<DOC>
	<DOCNO>NCT02096133</DOCNO>
	<brief_summary>Patients multiple sclerosis ( MS ) increase risk develop major depression . The investigator observe protective effect high vitamin D level risk depression MS . This might drive effect vitamin D stress-axis . Therefore , main goal present study ass whether high dose vitamin D supplementation result suppression stress-axis , measure decreased level cortisol .</brief_summary>
	<brief_title>Vitamin D3 Stress-axis MS</brief_title>
	<detailed_description>The lifetime incidence major depression Multiple Sclerosis ( MS ) 50 % . ( Patten et al . Neurology 2003 ; 61 ( 11 ) :1524-7 ) Our group report negative correlation vitamin D status depression score Hospital Anxiety Depression Scale ( HADS ) cross-sectional dataset Dutch MS patient . ( Knippenberg et al . Acta Neurol Scand 2011 ; 124 ( 3 ) :171-5 ) This suggest interaction vitamin D biological mechanism affect susceptibility depression . Currently , two main hypothesis : 1 ) Vitamin D regulate hypothalamic stress axis MS. Based finding cortisol release hormone ( CRH ) -positive hypothalamic neuron brain MS patient stain positive vitamin D receptor ( VDR ) 1,25 ( OH ) 2D-24-hydroxylase ( 24-OHase ) . ( smolder et al . J Neuropathol Exp Neurol 2013 ; 72 ( 2 ) :91-105 ) 2 ) Vitamin D affect T cell cytokine profile hereby odds develop depression . Also non-MS depressed patient increase level pro-inflammatory cytokine detect ( Maes et al . Metab Brain Dis 2009 ; 24 : 27-53 ) . Vitamin D3 show potent promotor T cell regulation vitro vivo . ( Smolders et al . J Neuroimmunol 2008 ; 194:7-17 Smolders et al . PLoS One 2010 ; 5 : e15235 ) The main goal study ass whether supplementation high dos vitamin D3 result suppression saliva cortisol day-curves subject multiple sclerosis , explore whether pro-inflammatory cytokine profile T lymphocytes regulate .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Female Relapsing Remitting MS At start study &gt; 6 week clinical remission disease Age &gt; 18 year . Premenopausal Treated either immunemodulating treatment , currently register MS modulate treatment : Interferon beta 1a ( Rebif® ) , Interferon Beta 1b ( Betaferon® Avonex® ) , Glatiramer Acetate ( Copaxone® ) , dimethylfumarate ( Tecfidera® ) , teriflunomide ( Aubagio® ) ) fingolimod ( Gilenya® ) . Any contraindication vitamin D accord Summary Product Characteristics : Hypercalcaemia , hypervitaminosis D , nephrolithiasis , diseases condition result hypercalcaemia and/or hypercalciuria ( incl . primary hyperparathyroidism ) , severe renal impairment . Use dexamethasone systemic glucocorticosteroids &lt; 2 month prior first study visit Supplementation &gt; =1000 IU/d ( 25µg ) vitamin D2 D3 Medical history disturb vitamin D/ calcium metabolism low intake Present clinical ( major ) depression Present treatment antidepressant , benzodiazepine , neuroleptic . Treatment highdose dexamethasone MS exacerbation study . Pregnancy intention become pregnant study period .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Multiple sclerosis , vitamin D , HPA-axis , cortisol</keyword>
</DOC>